We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Boston Therapeutics Appoints Zbigniew J. Witczak to its Scientific Advisory Board
News

Boston Therapeutics Appoints Zbigniew J. Witczak to its Scientific Advisory Board

Boston Therapeutics Appoints Zbigniew J. Witczak to its Scientific Advisory Board
News

Boston Therapeutics Appoints Zbigniew J. Witczak to its Scientific Advisory Board

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Boston Therapeutics Appoints Zbigniew J. Witczak to its Scientific Advisory Board"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Boston Therapeutics, Inc. has appointed Zbigniew J. Witczak, Ph.D. to its Scientific Advisory Board (SAB). This brings the total number of Scientific Advisory Board members to six.

Dr. Witczak is professor and chair of the Department of Pharmaceutical Sciences at Wilkes University in Wilkes-Barre, Pennsylvania, and has taught Principles of Bioorganic and Medicinal Chemistry at the Nesbitt School of Pharmacy at Wilkes University for the past 14 years.

A member of the American Chemical Society, he is the recipient of numerous honors and awards, including Selected 2011 ACS Fellow of the American Chemical Society and Elected U.S. Representative to the International Carbohydrate Organization in 2006.

He is the author or coauthor of more than 75 research articles in the area of carbohydrate chemistry. He received Ph.D. and M.S. degrees in organic chemistry from Medical University in Lódz, Poland.

Dr. Witczak said, "The need for innovative treatments in diabetes has never been greater, in light of the increasing numbers of Americans with this disease. I believe Boston Therapeutics is doing valuable and innovative work in this area, and I am looking forward to helping guide the Company's development of its diabetes-related treatments."

Rom E. Eliaz, Ph.D., MBA, chair of the Boston Therapeutics' Scientific Advisory Board and member of the Company's Board of Directors, said, "The appointment of Dr. Witczak to the Board brings Boston Therapeutics an additional distinguished expert who will provide unique expertise to help guide the Company through its future endeavors."

David Platt, Chief Executive Officer of Boston Therapeutics, said, "We are extremely fortunate to have attracted Dr. Witczak to serve on our Scientific Advisory Board. We believe his decades of research experience will be a significant asset to us as we continue to seek the best path forward to helping those with diabetes."

Advertisement